

United States Dry Eye Disease Market Forecast 2024-2032

Market Report | 2024-10-12 | 147 pages | Inkwood Research

AVAILABLE LICENSES:

- Single User Price \$1100.00
- Global Site License \$1500.00

Report description:

KEY FINDINGS

The United States dry eye disease market is projected to grow at a CAGR of 5.09% from 2024 to 2032. The market was valued at \$2103.11 by 2023, reaching a revenue of \$3313.01 million by 2032. One of the primary drivers fueling the country's market growth is the increasing prevalence of dry eye disease among the aging population, which is more prone to tear production issues due to age-related changes. Additionally, lifestyle factors, such as the growing use of digital devices and prolonged screen exposure, are significantly contributing to the rising incidence of dry eye disease symptoms across various age groups.

MARKET INSIGHTS

Chronic conditions such as diabetes, autoimmune diseases, and post-operative effects from procedures like cataract surgery are contributing to an expanding patient base for dry eye disease. Growing awareness of dry eye diagnosis and treatment, coupled with advancements in therapeutic and diagnostic products, is further driving market growth. In the United States, capsules and tablets have emerged as key treatment options, particularly for patients seeking long-term relief from moderate to severe forms of dry eye disease. These oral medications help manage underlying issues such as inflammation and autoimmune responses, which are common causes of the condition.

The increasing use of digital screens-computers, smartphones, and tablets-has also become a significant factor contributing to dry eye symptoms, as prolonged screen time reduces blinking rates. This digital exposure, which is prevalent among a large segment of the population, is fueling the market's expansion. According to the National Eye Institute (NEI), over 16 million people in the United States are diagnosed with dry eye disease. Data from the United States National Health and Wellness Survey (NHWS) also shows that gender differences in the prevalence of dry eye disease increase with age, indicating that the condition is likely to rise further as the population ages-boosting market growth.

Restasis was the primary treatment available for dry eyes in the United States until Xiidra entered the market in 2016. The approval of Sun Pharma's Cequa in 2018 marked another significant development. Additionally, several new drugs are currently in the pipeline, enhancing market prospects. For example, RegeneRx's RGN-259, a TGF- β -based sterile and preservative-free eye drop, is undergoing Phase II/III clinical trials as a novel treatment for dry eye and neurotrophic keratitis, involving 317 patients.

The US dry eye disease market is positioned for steady growth, with capsules and tablets playing a critical role in the long-term management of the condition. These dosage forms remain vital due to their convenience and effectiveness in addressing underlying causes of dry eye disease, making them an essential component of the treatment landscape.

SEGMENTATION ANALYSIS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The United States dry eye disease market segmentation includes distribution channel, type, dosage, and product. The dosage segment is further classified into eye drops, eye solutions, ointments, gels, and capsules & tablets.

Eye solutions are a widely utilized dosage type for the treatment of dry eye disease, offering immediate and localized relief by directly delivering therapeutic agents to the ocular surface. These solutions are typically available as drops and are designed to hydrate the eye, replenish the tear film, and alleviate symptoms such as irritation, redness, and burning caused by dry eye. They can contain various active ingredients like lubricants, anti-inflammatory agents, and even secretagogues, which stimulate natural tear production.

Sodium hyaluronate is a common component, known for its moisture-retaining properties, while other solutions may include anti-inflammatory compounds like ciclosporin or lifitegrast to address inflammation associated with dry eye disease. Eye solutions are available in both preservative-free and preserved formulations, with preservative-free options being ideal for individuals who require frequent application or have sensitive eyes. Additionally, some advanced eye solutions are designed with viscoadaptive or lipid-based formulations that enhance their retention on the ocular surface, providing longer-lasting relief. This makes eye solutions a convenient, versatile, and effective option for managing both mild and severe cases of dry eye disease.

COMPETITIVE INSIGHTS

Major companies operating in the United States dry eye disease market include Bausch Health Companies Inc, Johnson & Johnson, AFT Pharmaceuticals, etc.

Bausch Health Companies Inc develops, manufactures, and markets medical devices, over-the-counter (OTC) products, and pharmaceuticals, focusing on areas such as dermatology, gastroenterology, eye health, neurology, and consumer health. The company offers both generic and branded products and operates globally, including in regions like the US, Canada, Africa, Latin America, Europe, and the Middle East. It has manufacturing facilities in the United States, Brazil, Germany, and Canada. Bausch Health is headquartered in Laval, Quebec, Canada.

Table of Contents:

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. METHODOLOGY

1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

2.3. SCOPE OF STUDY

2.4. CRISIS SCENARIO ANALYSIS

2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET

2.5. MAJOR MARKET FINDINGS

2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE

2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE

2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS

2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES

3. MARKET DYNAMICS

3.1. KEY DRIVERS

3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS

3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE

3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE

3.2. KEY RESTRAINTS

3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
- 3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
- 4. KEY ANALYTICS
 - 4.1. PARENT MARKET ANALYSIS
 - 4.2. KEY MARKET TRENDS
 - 4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
 - 4.3. PORTER'S FIVE FORCES ANALYSIS
 - 4.3.1. BUYERS POWER
 - 4.3.2. SUPPLIERS POWER
 - 4.3.3. SUBSTITUTION
 - 4.3.4. NEW ENTRANTS
 - 4.3.5. INDUSTRY RIVALRY
 - 4.4. GROWTH PROSPECT MAPPING
 - 4.4.1. GROWTH PROSPECT MAPPING FOR UNITED STATES DRY EYE DISEASE MARKET
 - 4.5. MARKET MATURITY ANALYSIS
 - 4.6. MARKET CONCENTRATION ANALYSIS
 - 4.7. VALUE CHAIN ANALYSIS
 - 4.7.1. RESEARCH AND DEVELOPMENT
 - 4.7.2. MANUFACTURING
 - 4.7.3. DISTRIBUTORS
 - 4.7.4. POST-SALES MONITORING
- 5. MARKET BY TYPE
 - 5.1. OTC
 - 5.2. PRESCRIPTION
- 6. MARKET BY PRODUCT
 - 6.1. ANTI-INFLAMMATORY DRUGS
 - 6.1.1. CYCLOSPORINE
 - 6.1.2. CORTICOSTEROID
 - 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
 - 6.2. ARTIFICIAL TEARS
 - 6.3. PUNCTAL PLUGS
 - 6.4. SECRETAGOGUES
 - 6.5. OTHER PRODUCTS
- 7. MARKET BY DOSAGE
 - 7.1. EYE DROPS
 - 7.2. EYE SOLUTIONS
 - 7.3. OINTMENTS
 - 7.4. GELS
 - 7.5. CAPSULES & TABLETS
- 8. MARKET BY DISTRIBUTION CHANNEL
 - 8.1. HOSPITAL PHARMACIES
 - 8.2. INDEPENDENT PHARMACIES AND DRUG STORES
 - 8.3. ONLINE PHARMACIES/STORES
- 9. COMPETITIVE LANDSCAPE
 - 9.1. KEY STRATEGIC DEVELOPMENTS
 - 9.1.1. MERGERS & ACQUISITIONS
 - 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
- 9.2. COMPANY PROFILES
 - 9.2.1. ALCON
 - 9.2.1.1. COMPANY OVERVIEW
 - 9.2.1.2. PRODUCT LIST
 - 9.2.1.3. STRENGTHS & CHALLENGES
 - 9.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
 - 9.2.2.1. COMPANY OVERVIEW
 - 9.2.2.2. PRODUCT LIST
 - 9.2.2.3. STRENGTHS & CHALLENGES
 - 9.2.3. BAUSCH HEALTH COMPANIES INC
 - 9.2.3.1. COMPANY OVERVIEW
 - 9.2.3.2. PRODUCT LIST
 - 9.2.3.3. STRENGTHS & CHALLENGES
 - 9.2.4. JOHNSON & JOHNSON
 - 9.2.4.1. COMPANY OVERVIEW
 - 9.2.4.2. PRODUCT LIST
 - 9.2.4.3. STRENGTHS & CHALLENGES
 - 9.2.5. AFT PHARMACEUTICALS
 - 9.2.5.1. COMPANY OVERVIEW
 - 9.2.5.2. PRODUCT LIST
 - 9.2.5.3. STRENGTHS & CHALLENGES
 - 9.2.6. NOVARTIS AG
 - 9.2.6.1. COMPANY OVERVIEW
 - 9.2.6.2. PRODUCT LIST
 - 9.2.6.3. STRENGTHS & CHALLENGES
 - 9.2.7. SUN PHARMACEUTICAL INDUSTRIES LTD
 - 9.2.7.1. COMPANY OVERVIEW
 - 9.2.7.2. PRODUCTS LIST
 - 9.2.7.3. STRENGTHS & CHALLENGES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States Dry Eye Disease Market Forecast 2024-2032

Market Report | 2024-10-12 | 147 pages | Inkwood Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$1100.00
	Global Site License	\$1500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com